Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2 V617F and Are Strongly Associated With Anemia and Thrombocytopenia

Ayalew Tefferi, MD, Christy Finke, BS, Terra L Lasho, MT, (ASCP), Emnet A Wassie, MD, Ryan A Knudson, Rhett P Ketterling, Curtis A Hanson, MD, Animesh Pardanani, MBBS, PhD

Blood (2013) 122 (21): 4060.

https://doi.org/10.1182/blood.V122.21.4060.4060

Published: 2013

Journal Articles

Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients

Animesh Pardanani, MBBS, PhD, Ramy A Abdelrahman, MBBCh, Kebede Begna, MD, Darci Zblewski, RN, CNP, Aref Al-Kali, MD, Mrinal M. Patnaik, MBBS, William Hogan, MD, Terra L Lasho, MT, (ASCP), Christy Finke, BS, Curtis A. Hanson, MD, Mark R. Litzow, MD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 4048.

https://doi.org/10.1182/blood.V122.21.4048.4048

Published: 2013

Journal Articles

Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients

Ayalew Tefferi, MD, Paola Guglielmelli, MD, Terra L Lasho, MT, (ASCP), Christy Finke, BS, Emnet A Wassie, MD, Ryan A Knudson, Rhett P Ketterling, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Alessandro M Vannucchi, MD

Blood (2013) 122 (21): 1587.

https://doi.org/10.1182/blood.V122.21.1587.1587

Published: 2013

Journal Articles

Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis

Animesh D. Pardanani, MBBS, PhD, Terra L Lasho, MT(ASCP), Christy Finke, BS, Ramy A. Abdelrahman, MBBCh, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 2824.

https://doi.org/10.1182/blood.V122.21.2824.2824

Published: 2013

Journal Articles

Chronic Neutrophilic Leukemia With Concurrent CSF3R and SETBP1 Mutations: Single Colony Clonality Studies, In Vitro Sensitivity To JAK Inhibitors and Lack Of Treatment Response To Ruxolitinib

Terra L Lasho, MT, (ASCP), Alice Mims, MD, Rebecca R. Laborde, PhD, Christy Finke, BS, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 2830.

https://doi.org/10.1182/blood.V122.21.2830.2830

Published: 2013

Journal Articles

Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis

Blood (2013) 122 (21): 104.

https://doi.org/10.1182/blood.V122.21.104.104

Published: 2013

Journal Articles

Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

Ayalew Tefferi, MD, Kebede Begna, MD, Rebecca R. Laborde, PhD, Mrinal M Patnaik, MBBS, Terra L Lasho, MT, (ASCP), Darci Zblewski, Christy Finke, BS, Lauren Schimek, Betsy R. LaPlant, Curtis A. Hanson, MD, Monic J. Stuart, MD, MPH, Animesh Pardanani, MBBS, PhD

Blood (2013) 122 (21): 662.

https://doi.org/10.1182/blood.V122.21.662.662

Published: 2013

Journal Articles

ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients

Mrinal M Patnaik, MBBS, Raphael Itzykson, Terra L Lasho, MT, (ASCP), Olivier Kosmider, MD, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Ryan A Knudson, Rhett P Ketterling, Ayalew Tefferi, MD, Eric Solary

Blood (2013) 122 (21): 1510.

https://doi.org/10.1182/blood.V122.21.1510.1510

Published: 2013

Journal Articles

Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms

Qiang Jeremy Wen, PhD, MD, Benjamin Goldenson, Sebastien Malinge, PhD, Brady L Stein, MD MHS, Terra L Lasho, MT, (ASCP), Lawrence Breyfogle, Rachael Schultz, Qiong Yang, Laure gilles-Gendre, Priya Koppikar, Omar Abdel-Wahab, MD, Benjamin L. Ebert, MD, PhD, Animesh Pardanani, MBBS, PhD, Sandeep Gurbuxani, MBBS, PhD, Ross L. Levine, MD, Ann Mullally, MD, Ayalew Tefferi, MD, John D Crispino, PhD

Blood (2013) 122 (21): 109.

https://doi.org/10.1182/blood.V122.21.109.109

Published: 2013

Journal Articles

Gene Expression Profiling within the Context of JAK Inhibitor Therapy for Myelofibrosis: Correlation with Treatment Effect and Anemia Response

Animesh Pardanani, MBBS, PhD, Rebecca R. Laborde, PhD, Terra L Lasho, MT, (ASCP), Christy Finke, BS, Alexey A. Leontovich, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 1751.

https://doi.org/10.1182/blood.V120.21.1751.1751

Published: 2012

Journal Articles

Spliceosome Mutations Involving SRSF2 , SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis

Mrinal M. Patnaik, MBBS, MD, Terra L Lasho, MT, (ASCP), Christy Finke, BS, Curtis A Hanson, MD, Janice M Hodnefield, MS, MT(ASCP), Ryan A Knudson, Rhett P Ketterling, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 1711.

https://doi.org/10.1182/blood.V120.21.1711.1711

Published: 2012

Journal Articles

Aberrant Megakaryocyte Gene Expression Contributes to Primary Myelofibrosis.

Laure Gilles, PhD, Christy Finke, BS, Terra L Lasho, MT, (ASCP), Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, John Crispino, PhD

Blood (2012) 120 (21): 2867.

https://doi.org/10.1182/blood.V120.21.2867.2867

Published: 2012

Journal Articles

Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis.

Animesh Pardanani, MBBS, PhD, Biruk Mengistu, M.D., Christy Finke, BS, Terra L Lasho, MT, (ASCP), Ayalew Tefferi, MD

Blood (2012) 120 (21): 2831.

https://doi.org/10.1182/blood.V120.21.2831.2831

Published: 2012

Journal Articles

Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels.

Animesh Pardanani, MBBS, PhD, Christy Finke, BS, Terra L Lasho, MT, (ASCP), Ayalew Tefferi, MD

Blood (2012) 120 (21): 2836.

https://doi.org/10.1182/blood.V120.21.2836.2836

Published: 2012

Journal Articles

Phenotypic and Prognostic Correlates of Spliceosome Mutations ( SRSF2 , SF3B1 , U2AF35 ) in Chronic Myelomonocytic Leukemia with ≥ 1% Ring Sideroblasts.

Mrinal M. Patnaik, MBBS, MD, Terra L Lasho, MT, (ASCP), Curtis A Hanson, MD, Janice M Hodnefield, MS, MT(ASCP), Ryan A Knudson, Rhett P Ketterling, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 2803.

https://doi.org/10.1182/blood.V120.21.2803.2803

Published: 2012

Journal Articles

Prognostic Interactions Between SRSF2 , ASXL1 , and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus

Terra L. Lasho, MT, (ASCP), Naseema Gangat, MD, Christy Finke, BS, Rebecca R. Laborde, PhD, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Ryan A. Knudson, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 430.

https://doi.org/10.1182/blood.V120.21.430.430

Published: 2012

Journal Articles

IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,

Animesh Pardanani, MBBS, PhD, Christy Finke, BS, Terra L Lasho, MT, (ASCP), Aref Al-Kali, MD, Kebede Begna, MD, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3795.

https://doi.org/10.1182/blood.V118.21.3795.3795

Published: 2011

Journal Articles

TP53 mutations and Polymorphisms in Primary Myelofibrosis,

Sania S Raza, MD, David Viswanatha, MD, Lori A Erickson, MD, Terra L Lasho, MT(ASCP), Christy Finke, BS, Ryan A Knudson, Rhett Ketterling, MD, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3840.

https://doi.org/10.1182/blood.V118.21.3840.3840

Published: 2011

Journal Articles

Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,

Mrinal M. Patnaik, MBBS, MD, Curtis A Hanson, Nanna Sulai, Janice M Hodnefield, MS, MT(ASCP), Ryan A Knudson, Rhett P Ketterling, MD, Terra L Lasho, MT, (ASCP), Ayalew Tefferi, MD

Blood (2011) 118 (21): 3803.

https://doi.org/10.1182/blood.V118.21.3803.3803

Published: 2011

Journal Articles

Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,

Rakhee Vaidya, MD, Nanna Sulai, Shaina A Rozell, MD, Sania S Raza, MD, Sameer Parikh, MD, Thitina Jimma, MD, Christy Finke, BS, Terra L Lasho, MT, (ASCP), Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3850.

https://doi.org/10.1182/blood.V118.21.3850.3850

Published: 2011

NARROW

U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2 V617F and Are Strongly Associated With Anemia and Thrombocytopenia

Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients

Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients

Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis

Chronic Neutrophilic Leukemia With Concurrent CSF3R and SETBP1 Mutations: Single Colony Clonality Studies, In Vitro Sensitivity To JAK Inhibitors and Lack Of Treatment Response To Ruxolitinib

Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis

Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients

Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms

Gene Expression Profiling within the Context of JAK Inhibitor Therapy for Myelofibrosis: Correlation with Treatment Effect and Anemia Response

Spliceosome Mutations Involving SRSF2 , SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis

Aberrant Megakaryocyte Gene Expression Contributes to Primary Myelofibrosis.

Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis.

Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels.

Phenotypic and Prognostic Correlates of Spliceosome Mutations ( SRSF2 , SF3B1 , U2AF35 ) in Chronic Myelomonocytic Leukemia with ≥ 1% Ring Sideroblasts.

Prognostic Interactions Between SRSF2 , ASXL1 , and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus

IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,

TP53 mutations and Polymorphisms in Primary Myelofibrosis,

Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,

Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only